Randomized, multicenter trial to assess the efficacy, safety and tolerability of a single dose of a novel AMPA receptor antagonist BGG492 for the treatment of acute migraine attacks

• Published in: Cephalalgia Vol. 34; no. 2; pp. 103 - 113
• Main Authors: Gomez-Mancilla, Baltazar, Brand, Ronald, Jürgens, Tim P, Göbel, Harmut, Sommer, Claudia, Straube, Andreas, Evers, Stefan, Sommer, Martin, Campos, Victor, Kalkman, Hans O, Hariry, Sam, Pezous, Nicole, Johns, Donald, Diener, Hans-Christoph
• Format: Journal Article
• Language: English
• Published: London, England SAGE Publications 01.02.2014
• Subjects: Acute Disease; Adult; Anticonvulsants - administration & dosage; Anticonvulsants - adverse effects; Anticonvulsants - pharmacokinetics; Double-Blind Method; Female; Humans; Male; Middle Aged; Migraine Disorders - drug therapy; Placebos; Quinazolinones - administration & dosage; Quinazolinones - adverse effects; Quinazolinones - pharmacokinetics; Receptors, AMPA - antagonists & inhibitors; Serotonin 5-HT1 Receptor Agonists - administration & dosage; Serotonin 5-HT1 Receptor Agonists - adverse effects; Serotonin 5-HT1 Receptor Agonists - pharmacokinetics; Sumatriptan - administration & dosage; Sumatriptan - adverse effects; Sumatriptan - pharmacokinetics; Treatment Outcome; AMPA receptor antagonist; Migraine attack; sumatriptan

Background Glutamate is implicated in migraine pathophysiology; amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor antagonists represent a potential therapeutic approach because of their anti-excitatory actions. Methods This randomized, double-blind, proof-of-concept study assessed...